Assessment of brain natriuretic peptide and copeptin as correlates of blood pressure in chronic hypertensive pregnant women

Okwor, Chika; Adedapo, Kayode Solomon; Bello, Oluwasomidoyin Olukemi; Meka, Ijeoma A; Okwor, Chukwuemeka V.; Uche, Chukwuemelie Z.; Nwajiobi, Chiebonam E.; Nto-Ezimah, Uloaku Akubueze; Uchechukwu, Chisom E.; Arum, Ekene J.

doi:10.1186/s40885-022-00221-6

Cited by 3 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preeclampsia has been linked to an increase in brain natriuretic peptide levels [9]. This study attempted to answer the question of linking its increasing patterns as a feasible biomarking approach.…”

Section: Resultsmentioning

confidence: 99%

Utility of Brain Natriuretic Peptide as a Biomarker for Early Detection of Preeclampsia among Women Attending Antenatal Clinic in a Secondary Health Facility in Edo State, Nigeria

Atoe K.,

Onovughakpo-Sakpa O. E.,

Idogun E. S.

et al. 2023

JAMMR

View full text Add to dashboard Cite

Aims: The aim was to determine the suitability of brain natriuretic peptide as a biomarker for early detection of preeclampsia Study Design: This was a prospective case-control research. Place and Duration of Study: The study was conducted at the Department of Obstetrics and Gynecology, Central Hospital Benin, from November 2014 – December 2017. Methodology: The study involved 248 women who were organized into two groups; a preeclampsia group and a normotensive, normal pregnant group. Patients with a history of cardiovascular illness, renal disease, diabetes, thyroid disease, hepatic disease, or any other connected conditions, including urinary tract infections, were not eligible. Participants in the study underwent a single antecubital venipuncture, during which 5ml of venous blood was taken using a sterile disposable syringe. The enzyme linked immunosorbent assay was used to determine the levels of plasma brain natriuretic peptides. Results: The area under the curve (AUC) of BNP fluctuated across trimesters, reaching 87.1% in the second and 70.5% in the third (p 0.05). Sensitivity ranged from 80.0% in the second trimester to 79.1% in the third, but was 100% in the postpartum period for sensitivity, specificity, PPV, and negative predictive value. Reference values for BNP as a yardstick for questioning preeclampsia were determined to be 395.56 pg/ml at the start of the second trimester and 438.81 pg/ml at the end of the third trimester, with sensitivities and specificities all above 75%. Conclusion:BNP can be relied upon as a diagnostic biomarker for predicting preeclampsia.

show abstract

Section: Resultsmentioning

confidence: 99%

Utility of Brain Natriuretic Peptide as a Biomarker for Early Detection of Preeclampsia among Women Attending Antenatal Clinic in a Secondary Health Facility in Edo State, Nigeria

Atoe K.,

Onovughakpo-Sakpa O. E.,

Idogun E. S.

et al. 2023

JAMMR

View full text Add to dashboard Cite

show abstract

“…Many of the low L2G-scoring target-trait associations revealed by MR-coloc were unique to specific population groups but biologically plausible. For example, a signal near the gene cluster MTHFR-CLCN6-NPPA-NPPB (nearest gene: CLCN6) associated with higher B-type natriuretic peptide (NPPB) colocalized with a lower risk of pregnancy-induced hypertension-related phenotypes in Finns 42 . Some target-trait associations from MR-coloc were novel, i.e they were not supported by other evidence sources from the Open Targets platform, e.g.…”

Section: Figure 4: Genetic Colocalization Of Trans-mr Association Bet...mentioning

confidence: 99%

Systematic disease-agnostic identification of therapeutically actionable targets using the genetics of human plasma proteins.

Karim

Ariano

Schwartzentruber

et al. 2023

Preprint

View full text Add to dashboard Cite

Proteome-wide Mendelian randomization (MR) has emerged as a promising approach in uncovering novel therapeutic targets. However, genetic colocalization analysis has revealed that a third of MR associations lacked a shared causal signal between the protein and disease outcome, raising questions about the effectiveness of this approach. The impact of proteome-wide MR, stratified by cis-trans status, in the presence or absence of genetic colocalization, on therapeutic target identification remains largely unknown. In this study, we conducted genome-wide MR and cis/trans-genetic colocalization analyses using proteomic and complex trait genome-wide association studies. Using two different gold-standard datasets, we found that the enrichment of target-disease pairs supported by MR increased with more p-value stringent thresholds MR p-value, with the evidence of enrichment limited to colocalizing cis-MR associations. Using a phenome-wide proteogenetic colocalization approach, we identified 235 unique targets associated with 168 binary traits at high confidence (at colocalization posterior probability of shared signal > 0.8 and 5% FDR-corrected MR p-value). The majority of the target-trait pairs did not overlap with existing drug targets, highlighting opportunities to investigate novel therapeutic hypotheses. 42% of these non-overlapping target-trait pairs were supported by GWAS, interacting protein partners, animal models, and Mendelian disease evidence. These high confidence target-trait pairs assisted with causal gene identification and helped uncover translationally informative novel biology, especially from trans-colocalizing signals, such as the association of lower intestinal alkaline phosphatase with a higher risk of inflammatory bowel disease in FUT2 non-secretors. Beyond target identification, we used MR of colocalizing signals to infer therapeutic directions and flag potential safety concerns. For example, we found that most genetically predicted therapeutic targets for inflammatory bowel disease could potentially worsen allergic disease phenotypes, except for TNFRSF6B where we observed directionally consistent associations for both phenotypes. Our results are publicly available (https://mk31.shinyapps.io/mr_app2/), enabling others to use proteogenomic evidence to appraise therapeutic targets.

show abstract

Systematic disease-agnostic identification of therapeutically actionable targets using the genetics of human plasma proteins

Karim

Ariano

Schwartzentruber

et al. 2023

Preprint

View full text Add to dashboard Cite

Proteome-wide Mendelian randomization (MR) has emerged as a promising approach in uncovering novel therapeutic targets. However, genetic colocalization analysis has revealed that a third of MR associations lacked a shared causal signal between the protein and disease outcome, raising questions about the effectiveness of this approach. The impact of proteome-wide MR, stratified by cis-trans status, in the presence or absence of genetic colocalization, on therapeutic target identification remains largely unknown. In this study, we conducted genome-wide MR and cis/trans-genetic colocalization analyses using proteomic and complex trait genome-wide association studies. Using two different gold-standard datasets, we found that the enrichment of target-disease pairs supported by MR increased with more p-value stringent thresholds MR p-value, with the evidence of enrichment limited to colocalizing cis-MR associations. Using a phenome-wide proteogenetic colocalization approach, we identified 235 unique targets associated with 168 binary traits at high confidence (at colocalization posterior probability of shared signal > 0.8 and 5% FDR-corrected MR p-value). The majority of the target-trait pairs did not overlap with existing drug targets, highlighting opportunities to investigate novel therapeutic hypotheses. 42% of these non-overlapping target-trait pairs were supported by GWAS, interacting protein partners, animal models, and Mendelian disease evidence. Additionally, as previously reported, these high confidence target-trait pairs assisted with causal gene identification and helped uncover translationally informative novel biology, especially from trans-colocalizing signals, such as the association of lower intestinal alkaline phosphatase with a higher risk of inflammatory bowel disease in FUT2 non-secretors. Beyond target identification, we used MR of colocalizing signals to infer therapeutic directions and flag potential safety concerns. For example, we found that most genetically predicted therapeutic targets for inflammatory bowel disease could potentially worsen allergic disease phenotypes, except for TNFRSF6B where we observed directionally consistent associations for both phenotypes. Our results are publicly available (https://mk31.shinyapps.io/mr_app2/), enabling others to use proteogenomic evidence to appraise therapeutic targets.

show abstract

Assessment of brain natriuretic peptide and copeptin as correlates of blood pressure in chronic hypertensive pregnant women

Cited by 3 publications

References 30 publications

Utility of Brain Natriuretic Peptide as a Biomarker for Early Detection of Preeclampsia among Women Attending Antenatal Clinic in a Secondary Health Facility in Edo State, Nigeria

Utility of Brain Natriuretic Peptide as a Biomarker for Early Detection of Preeclampsia among Women Attending Antenatal Clinic in a Secondary Health Facility in Edo State, Nigeria

Systematic disease-agnostic identification of therapeutically actionable targets using the genetics of human plasma proteins.

Systematic disease-agnostic identification of therapeutically actionable targets using the genetics of human plasma proteins

Contact Info

Product

Resources

About